About Samuel Broder
Form D filings for GENEOS Therapeutics from 2020 to 2023 list Samuel Broder as director.
Samuel Broder first appears on SEC filings in 2020.
Experience
This experience comes from SEC filings. The years are when the filings name Samuel Broder in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Samuel Broder works with at each company, as listed on that company's latest Form D.
GENEOS Therapeutics, Inc. · Form D, Apr 13, 2023
LH
Laurent Humeau
Director
JE
James Eadie
Director
NS
Niranjan Sardesai
Chief Executive Officer and director
SL
Sangwoo Lee
Director
CC
Casey Cunningham
Director
TF
Ted Fjallman
Director